ArticleDermatology and therapy2026
Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.
Francesco D'Oria et al.PubMed ↗Publisher ↗
No numbers read from the abstract.